Abstract:Background: We performed this randomized controlled study protocol to investigate the efficacy and adverse effects of furosemide vs torasemide in patients with heart failure (HF). Method: The present study was authorized by the local research ethics committee of Shanxi Cardiovascular Hospital (no. 48736645) and informed consent was obtained from all patients. Patients were enrolled in a consecutive prospective manner on a voluntary basis. Patients who were aged 18years and older with HF who were eligible to enroll in this randomized trial. All patients had evidence of left ventricular systolic dysfunction, confirmed by echocardiographic or nuclear imaging. The exclusion criteria were left ventricular diastolic dysfunction only, or receipt of medical or pharmaceutical care in other health systems. The primary efficacy end point was the change in procollagen type I carboxyterminal peptide (PICP) serum levels between baseline and final visit. Secondary efficacy variables included parameters related to the clinical course of HF, such as body weight, presence of edema, signs and symptoms of HF, electrocardiogram and echocardiographic evaluation, amino-terminal pro brain-type natriuretic peptide (NTproBNP) serum levels measured by ELISA method, systolic blood pressure (SBP), diastolic blood pressure (DBP), heart rate, and renal function. Results: One hundred patients who met the inclusion criteria were included in our study, Table 1 showed the effects of furosemide and torsemide on measures of clinical outcomes. Discussion: Fluid overload is the primary cause of hospitalization among patients with HF. Preventing circulatory congestion requires careful control of dietary sodium and chronic administration of loop diuretics. Torasemide and furosemide are representatives of loop diuretics with an identical diuretic mechanism, but different pharmacokinetic properties and additional effects. There is a need for reliable conclusion regarding the comparison of furosemide and torasemide in patients with HF. Several limitation should be noted: 1. the small number of participants did not enable assessment of the impact of torasemide and furosemide in different clinically relevant subgroups that is, elderly, patients with chronic kidney disease, dilated cardiomyopathy; 2. short-term follow up might lead to underestimation of the complications; 3. methodological weakness in study design may affect the results. Future high quality studies were still required.

Effects of inhaled furosemide on exertional dyspnea in chronic obstructive pulmonary disease

Mechanisms of dyspnoea relief and improved exercise endurance after furosemide inhalation in COPD

Inhaled furosemide greatly alleviates the sensation of experimentally induced dyspnea

Effect of Inhaled Nebulized Furosemide (40 and 120 mg) on Breathlessness during Exercise in the Presence of External Thoracic Restriction in Healthy Men

Inhaled furosemide for relief of air hunger versus sense of breathing effort: a randomized controlled trial

Nebulized fentanyl does not improve exercise capacity or dyspnoea in fibrosing interstitial lung disease

Subdiuretic dose of furosemide enhances albuterol effects in asthmatic mice rather than bumetanide

Effect of Salbutamol Inhalation on Expiratory Flow Limitation in Patients with Chronic Obstructive Pulmonary Disease

Effect of furosemide in the treatment of high-altitude pulmonary edema

Comparative Effectiveness of Furosemide Vs Torasemide in Symptomatic Therapy in Heart Failure Patients: A Randomized Controlled Study Protocol.

Diuretic efficiency of a single dose of subcutaneous versus oral furosemide after heart failure hospitalization across diuretic resistance strata: A pilot randomized controlled trial

Inhaled furosemide effect on intravenous antigen challenge in ovalbumin sensitized guinea pigs

Effect of furosemide on the contraction of tracheal strips induced by calcium and some asthmogenic mediators in vitro

Exertional dyspnea in COPD: the dominant role of increased diaphragmatic activation

The efficacy of different training programs guided by cardiopulmonary exercise test goals for the treatment of male patients with chronic obstructive pulmonary disease

Avoiding Treatment in Hospital With Subcutaneous Furosemide for Worsening Heart Failure: A Pilot Study (AT HOME-HF)

Effect of furosemide combined with continuous renal replacement therapy on cardiorenal function and inflammatory response in patients with chronic renal and heart failure after hemodialysis

Nebulised furosemide for the treatment of patients with obstructive lung disease: a systematic review protocol

Effect and Its Side Effects of Long-Term Inhalation of Different Doses of Salmeterol/fluticasone on Moderate to Severe Stable Chronic Obstructive Pulmonary Disease Patients' Airway Inflammation and Physiological Function

Diuresis Efficacy in Ambulatory Congested Heart Failure Patients: Intra-patient Comparison of Three Diuretic Regimens (DEA-HF)

Exhaled nitric oxide, systemic inflammation, and the spirometric response to inhaled fluticasone propionate in severe chronic obstructive pulmonary disease: a prospective study